It has been 75 years since baseball icon Lou Gehrig declared himself the "luckiest man on the face of the earth," despite a diagnosis at age 35 of amyotrophic lateral sclerosis, a disease with no cure.
In the years since, polio has been virtually eradicated. Chemotherapy has made numerous cancers into curable illnesses. Chemically synthesized insulin treats diabetes. AIDS is kept in check with protease inhibitors. In those 75 years, ALS, the disease that often bears Gehrig's name, has taken the lives of 375,000 Americans, including Gehrig's life at age 37.
In those 75 years, one drug has received FDA approval in the treatment of ALS. That was in 1995.
That drug, riluzole, extends the life expectancy of patients by two to three months. Half of the 5,600 Americans diagnosed with ALS each year will die within three years.
"It's an awful disorder," said neurologist Ghazala Hayat.
The neurodegenerative disease attacks motor neurons in the brain and spinal cord, progressively weakening the body. Muscles twitch and cramp. Speech becomes thick and difficult to understand. Swallowing and walking become arduous, then impossible. Eventually, muscles that control breathing are affected.
The lack of a breakthrough belies the amount of research going on. So far, 20 genes have been identified as linked to ALS, and multiple drug trials are underway. "Each drug, even if it's a failure, shows us a pathway," said Hayat, who runs an ALS clinic at St. Louis University.
SLU's clinic is one of about 35 in the country to offer specialized, multidisciplined services to patients with ALS. More than a dozen practitioners, including neurologists, social workers, dietitians and therapists, work together to design a treatment plan.